Your browser doesn't support javascript.
loading
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Hurvitz, Sara A; Bardia, Aditya; Quiroga, Vanesa; Park, Yeon Hee; Blancas, Isabel; Alonso-Romero, José Luis; Vasiliev, Aleksandr; Adamchuk, Hryhoriy; Salgado, Marcelo; Yardley, Denise A; Berzoy, Oleksandr; Zamora-Auñón, Pilar; Chan, David; Spera, Gonzalo; Xue, Cloris; Ferreira, Erika; Badovinac Crnjevic, Tanja; Pérez-Moreno, Pablo Diego; López-Valverde, Vanesa; Steinseifer, Jutta; Fernando, Tharu M; Moore, Heather M; Fasching, Peter A.
Afiliação
  • Hurvitz SA; Breast Cancer Clinical Trials Program, Division of Hematology-Oncology, David Geffen School of Medicine, Clinical Research Unit, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA; Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: shurvitz@fredhutch.org.
  • Bardia A; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Quiroga V; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain; Catalan Institute of Oncology Badalona, Barcelona, Spain.
  • Park YH; Samsung Medical Center, Seoul, Republic of Korea.
  • Blancas I; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain; Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria de Granada, Granada, Spain; Medicine Department, Granada University, Granada, Spain.
  • Alonso-Romero JL; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain; Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain.
  • Vasiliev A; NSHI Road Clinical Hospital of JSC Russian Railways, Saint Petersburg, Russia.
  • Adamchuk H; Communal Enterprise Kryvyi Rih Oncology Dispensary, Kryvyi Rih, Ukraine.
  • Salgado M; Hospital do Câncer de Pernambuco, Recife, Brazil.
  • Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA.
  • Berzoy O; Communal Non-profit Enterprise Odesa Regional Clinical Hospital of Odesa Regional Council, Odesa, Ukraine.
  • Zamora-Auñón P; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain; Hospital Universitario La Paz, Madrid, Spain.
  • Chan D; Torrance Memorial Hunt Cancer Center, Torrance, CA, USA.
  • Spera G; Translational Research in Oncology (TRIO), Montevideo, Uruguay.
  • Xue C; F Hoffmann-La Roche, Toronto, ON, Canada.
  • Ferreira E; Roche Products, Welwyn Garden City, UK.
  • Badovinac Crnjevic T; F Hoffmann-La Roche, Basel, Switzerland.
  • Pérez-Moreno PD; Genentech, South San Francisco, CA, USA.
  • López-Valverde V; F Hoffmann-La Roche, Basel, Switzerland.
  • Steinseifer J; F Hoffmann-La Roche, Basel, Switzerland.
  • Fernando TM; Genentech, South San Francisco, CA, USA.
  • Moore HM; Genentech, South San Francisco, CA, USA.
  • Fasching PA; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Lancet Oncol ; 24(9): 1029-1041, 2023 09.
Article em En | MEDLINE | ID: mdl-37657462
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials Limite: Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials Limite: Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de publicação: Reino Unido